Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 3:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Muscle-Invasive Bladder Carcinoma Clear all
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer
Interventions
N803 plus Bacillus Calmette-Guerin (BCG)
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Superficial Bladder Cancer
Interventions
Whole bladder laser light treatment as an alternative to radical cystectomy, Photofrin
Procedure · Drug
Lead sponsor
North Florida/South Georgia Veterans Health System
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced May 22, 2026, 3:47 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
Interventions
Sacituzumab govitecan, Adaptive Radiotherapy
Drug · Radiation
Lead sponsor
Shilpa Gupta, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 22, 2026, 3:47 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced May 22, 2026, 3:47 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102, TURBT
Drug · Procedure
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
33
States / cities
Tucson, Arizona • Loma Linda, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced May 22, 2026, 3:47 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
High-Risk Non-Muscle-Invasive Bladder Cancer
Interventions
Cretostimogene Grenadenorepvec
Drug
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
65
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 22, 2026, 3:47 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A, Bladder Cancer TNM Staging Primary Tumor (T) T2B, Bladder Cancer TNM Staging Primary Tumor (T) T3, Bladder Cancer TNM Staging Primary Tumor (T) T3A, Bladder Cancer TNM Staging Primary Tumor (T) T3B, Bladder Cancer TNM Staging Regional Lymph Node (N) N0, Bladder Cancer TNM Staging Regional Lymph Node (N) N1, Bladder Cancer TNM Staging Distant Metastasis (M) M0
Interventions
Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200, Nivolumab Injection [Opdivo]
Drug
Lead sponsor
Taris Biomedical LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
6
States / cities
Hinsdale, Illinois • Rochester, New York • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced May 22, 2026, 3:47 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
retifanlimab, epacadostat, INCAGN02385, INCAGN02390
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced May 22, 2026, 3:47 AM EDT
Available No phase listed Expanded access
View directory record Official record
Conditions
NMIBC
Interventions
rMBCG
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 100 Years
U.S. locations
66
States / cities
Homewood, Alabama • Mobile, Alabama • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 22, 2026, 3:47 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced May 22, 2026, 3:47 AM EDT
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Bladder Carcinoma, Transition Cell Cancer, Muscle Invasive Bladder Carcinoma
Interventions
Transurethral Resection of the Bladder Tumor & Cystoscopy, Intensity Modulated Radiation Therapy, Expanded Prostate Cancer Index Composite Short Form 12, International Prostate Symptom Score
Procedure · Radiation · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Urinary Tract Urothelial Carcinoma
Interventions
Sunitinib
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced May 22, 2026, 3:47 AM EDT
Not listed No phase listed Observational
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced May 22, 2026, 3:47 AM EDT
Not listed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Muscle Invasive Bladder Cancer
Interventions
APL-1202 in combination with tislelizumab, Tislelizumab alone
Drug
Lead sponsor
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced May 22, 2026, 3:47 AM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms
Interventions
enfortumab vedotin (EV), pembrolizumab, cisplatin, carboplatin, gemcitabine
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
83
States / cities
Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 22, 2026, 3:47 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer
Interventions
Nivolumab, Gemcitabine, Cisplatin
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
26
States / cities
Tucson, Arizona • Sacramento, California • Littleton, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 22, 2026, 3:47 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma
Interventions
AMVAC + Nivolumab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced May 22, 2026, 3:47 AM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC V8
Interventions
Biopsy, Daratumumab, Laboratory Biomarker Analysis, Metastasectomy, Nephrectomy
Procedure · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced May 22, 2026, 3:47 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
AU-011, AU-011 in Combination with Medical Laser Adminstration, AU-011 in Combination with Medical Laser Administration
Drug · Combination Product
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 22, 2026, 3:47 AM EDT
Recruiting Phase 4 Interventional
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Carcinoma
Interventions
Accelerometry, BCG Solution, Electronic Health Record Review, Patient Discharge, Survey Administration
Procedure · Biological · Other + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced May 22, 2026, 3:47 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Bladder Cancer
Interventions
Enfortumab vedotin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced May 22, 2026, 3:47 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma, Ureter Carcinoma, Urinary Bladder Carcinoma, Urethra Carcinoma, Muscle Invasive Bladder Cancer
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
41
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer
Interventions
Bacille Calmette-Guerrin (BCG), Lenalidomide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced May 22, 2026, 3:47 AM EDT